United States News Todas as matérias

S&P Global (NYSE:SPGI) has completed its acquisition of blockchain security company OpenZeppelin, expanding its digital asset risk assessment capabilities to cover the technology underlying tokenized financial products and decentralized finance.

Regeneron Pharmaceuticals (NASDAQ:REGN) announced a $270 million extension of its agreement with the Biomedical Advanced Research and Development Authority to supply additional doses of Inmazeb for U.S. preparedness against Ebola outbreaks.

Fate Therapeutics (NASDAQ:FATE) presented preliminary Phase 1 clinical results for FT819 showing renal responses in two evaluable patients with lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

CAE (NASDAQ:CAE) has signed a definitive agreement to sell Flightscape, its airline operations software business, to aviation technology provider SITA for an enterprise value of US$500 million.

City Holding Company (NASDAQ:CHCO) reported third-quarter 2026 net income of $34.6 million and record diluted earnings of $2.43 per share, compared with $33.3 million and $2.35 per share in the second quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS) reported a third-quarter 2026 net loss of $25.4 million, compared with $26.5 million a year earlier, as the biotechnology company prepares to release Phase 2 Alzheimer's disease trial results in November.

Verizon Communications (NYSE:VZ) reported third-quarter 2026 revenue of $34.3 billion, an increase of 1.5% year over year, while consolidated net income rose 5.2% to $5.3 billion and earnings per share increased 6.8% to $1.25.

HBT Financial (NASDAQ:HBT) reported third-quarter 2026 net income of $31.4 million, compared with $27.8 million in the preceding quarter, while diluted earnings per share increased to $0.86 from $0.76.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of investigational antiviral zelicapavir in adults at high risk of severe outcomes from respiratory syncytial virus infection.

Genmab A/S (NASDAQ:GMAB) reported updated Phase 2 results showing median overall survival of 28.2 months for petosemtamab combined with pembrolizumab in first-line treatment of recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma.

Alliance Resource Partners (NASDAQ:ARLP) reported third-quarter 2026 revenue of $603 million, an increase of 5.5% year over year, while net income attributable to the partnership climbed 46.8% to $139.6 million.

Bank of Hawai‘i Corporation (NYSE:BOH) reported third-quarter 2026 net income of $64.3 million, or $1.49 per diluted common share, compared with $63.8 million and $1.47 per share in the preceding quarter.

Ovintiv (NYSE:OVV) agreed to acquire Logan Energy in an all-cash transaction valued at approximately $890 million, including expected closing net debt, as the energy producer seeks to expand its Canadian asset portfolio.

Vertiv Holdings (NYSE:VRT) has completed its acquisition of King Environmental Services (KES), expanding its thermal management services across Europe, the Middle East and Africa.

Eikon Therapeutics (NASDAQ:EIKN) presented updated Phase 2 TeLuRide-005 results showing a 63.1% objective response rate with EIK1001 combined with pembrolizumab and chemotherapy in previously untreated patients with stage 4 non-small cell lung cancer.

Amanat Acquisition (NASDAQ:AMAN) and Corxel US signed a definitive business combination agreement intended to create a publicly traded biopharmaceutical company focused on obesity treatments, with approximately $377 million in potential gross proceeds.

EQT Corporation (NYSE:EQT) announced an agreement to acquire Range Resources (NYSE:RRC) in an all-stock transaction expected to create a natural gas producer with a pro forma enterprise value exceeding $50 billion.

BioNTech (NASDAQ:BNTX) and DualityBio announced that trastuzumab pamirtecan met the primary endpoint of the global Phase 3 DYNASTY-Breast02 trial in patients with HR-positive, HER2-low metastatic breast cancer.

HUTCHMED (NASDAQ:HCM) reported Phase III SANOVO results showing that ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in previously untreated EGFR-mutated lung cancer patients.

Borr Drilling (NYSE:BORR) said five personnel remained unaccounted for after its Prospector 5 jack-up drilling rig sank offshore Gabon on October 24, 2026.

Phathom Pharmaceuticals (NASDAQ:PHAT) announced that the U.S. Food and Drug Administration established a public docket seeking comments on regulatory questions involving VOQUEZNA's exclusivity protections through May 3, 2032.

Elbit Systems (NASDAQ:ESLT) announced approximately $200 million in contracts to supply airborne intelligence, surveillance, targeting and training solutions to an undisclosed Asia-Pacific country.

Oil prices fell around 2% on Monday, October 26, 2026, as hopes of easing hostilities between the United States and Iran reduced some geopolitical concerns following last week's rally.

HUTCHMED (NASDAQ:HCM) reported positive results from its 338-patient Phase III SAFFRON lung cancer trial, showing that ORPATHYS plus TAGRISSO significantly improved survival compared with platinum-based chemotherapy.